Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its fourth quarter and full year 2024 financial results on February 26, 2025, and will also provide a corporate update [1] Group 1: Upcoming Events - Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on February 26, 2025, to discuss financial results [1] - David Meeker, M.D., will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 1:10 p.m. ET [2] Group 2: Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead product, IMCIVREE® (setmelanotide), is approved by the FDA for treating obesity and hunger control in patients with specific genetic conditions [4][5] - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications [4][6] Group 3: Product Indications - In the U.S., setmelanotide is indicated for patients aged 2 years and older with syndromic or monogenic obesity due to specific genetic deficiencies [5] - In the EU and UK, it is indicated for obesity and hunger control associated with genetically confirmed conditions in adults and children aged 2 years and above [6] Group 4: Limitations and Contraindications - Setmelanotide is not indicated for obesity due to benign variants or other types of obesity not related to specific genetic deficiencies [7][8] - Serious hypersensitivity reactions have been reported, and the drug is contraindicated in patients with prior serious hypersensitivity to it [9] Group 5: Warnings and Precautions - Patients may experience disturbances in sexual arousal, depression, and hypersensitivity reactions [10][11][12] - Skin hyperpigmentation and the development of new melanocytic nevi have been observed, necessitating regular skin examinations [13] Group 6: Adverse Reactions - Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, and depression [15]